Robert C. Wong's most recent trade in Cytokinetics Inc was a trade of 766 Common Stock done . Disclosure was reported to the exchange on Dec. 3, 2024.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Cytokinetics Inc | Robert C. Wong | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Dec 2024 | 766 | 18,655 (0%) | 0% | 0 | Common Stock | |
Cytokinetics Inc | Robert C. Wong | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Dec 2024 | 764 | 18,162 (0%) | 0% | 0 | Common Stock | |
Cytokinetics Inc | Robert C. Wong | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 51.51 per share. | 03 Dec 2024 | 273 | 17,889 (0%) | 0% | 51.5 | 14,062 | Common Stock |
Cytokinetics Inc | Robert C. Wong | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 48.88 per share. | 03 Jun 2024 | 13,011 | 16,653 (0%) | 0% | 48.9 | 635,978 | Common Stock |
Cytokinetics Inc | Robert C. Wong | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2024 | 4,079 | 29,664 (0%) | 0% | 0 | Common Stock | |
Cytokinetics Inc | Robert C. Wong | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2024 | 3,308 | 3,308 | - | - | Non-Qualified Stock Option (Right to Buy) | |
Cytokinetics Inc | Robert C. Wong | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2024 | 1,403 | 1,403 | - | - | Incentive Stock Option (Right to Buy) | |
Cytokinetics Inc | Robert C. Wong | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 67.68 per share. | 04 Mar 2024 | 1,783 | 26,442 (0%) | 0% | 67.7 | 120,673 | Common Stock |
Cytokinetics Inc | Robert C. Wong | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 66.88 per share. | 04 Mar 2024 | 857 | 25,585 (0%) | 0% | 66.9 | 57,316 | Common Stock |
Cytokinetics Inc | Robert C. Wong | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 9,536 | 9,536 | - | - | Non-Qualified Stock Option (Right to Buy) | |
Cytokinetics Inc | Robert C. Wong | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 6,000 | 27,613 (0%) | 0% | 0 | Common Stock | |
Cytokinetics Inc | Robert C. Wong | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 2,464 | 2,464 | - | - | Incentive Stock Option (Right to Buy) | |
Cytokinetics Inc | Robert C. Wong | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 39.13 per share. | 06 Mar 2023 | 692 | 21,613 (0%) | 0% | 39.1 | 27,078 | Common Stock |
Cytokinetics Inc | Robert C. Wong | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 39.60 per share. | 02 Mar 2023 | 2,484 | 22,305 (0%) | 0% | 39.6 | 98,366 | Common Stock |
Cytokinetics Inc | Robert C. Wong | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 45.21 per share. | 21 Feb 2023 | 2,234 | 24,789 (0%) | 0% | 45.2 | 100,999 | Common Stock |
Cytokinetics Inc | Robert C. Wong | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.13 per share. | 16 Feb 2023 | 510 | 27,023 (0%) | 0% | 44.1 | 22,506 | Common Stock |
Cytokinetics Inc | Robert C. Wong | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 45.00 per share. | 03 Feb 2023 | 3,004 | 27,533 (0%) | 0% | 45 | 135,180 | Common Stock |
Cytokinetics Inc | Robert C. Wong | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 40.68 per share. | 14 Nov 2022 | 2,100 | 30,537 (0%) | 0% | 40.7 | 85,428 | Common Stock |
Cytokinetics Inc | Robert C. Wong | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 36.83 per share. | 07 Mar 2022 | 1,384 | 31,960 (0%) | 0% | 36.8 | 50,973 | Common Stock |
Cytokinetics Inc | Robert C. Wong | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2022 | 10,364 | 10,364 | - | - | Non-Qualified Stock Option (right to buy) | |
Cytokinetics Inc | Robert C. Wong | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2022 | 7,500 | 33,344 (0%) | 0% | 0 | Common Stock | |
Cytokinetics Inc | Robert C. Wong | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2022 | 3,636 | 3,636 | - | - | Incentive Stock Option (right to buy) | |
Cytokinetics Inc | Robert C. Wong | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 37.63 per share. | 02 Mar 2022 | 1,447 | 25,844 (0%) | 0% | 37.6 | 54,451 | Common Stock |
Cytokinetics Inc | Robert C. Wong | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2022 | 1,250 | 27,291 (0%) | 0% | 0 | Common Stock | |
Cytokinetics Inc | Robert C. Wong | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2022 | 737 | 26,041 (0%) | 0% | 0 | Common Stock |